Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2024

Agile Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Aug '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
105959251148
Market Cap Growth
--46.88%-84.44%-76.39%69.26%648.87%
Enterprise Value
85561195130
Last Close Price
1.511.9511.35976.205740.005000.00
PE Ratio
--0.29-0.19-0.67-4.69-6.64
PS Ratio
0.310.250.8514.45335.03-
PB Ratio
--0.30-1.6615.135.093.24
P/FCF Ratio
--0.51-0.26-0.91-5.26-9.39
P/OCF Ratio
--0.51-0.26-0.91-5.30-9.45
EV/Sales Ratio
0.360.230.4814.87260.54-
EV/EBITDA Ratio
--0.23-0.13-0.89-4.00-6.96
EV/EBIT Ratio
--0.23-0.13-0.86-3.98-6.90
EV/FCF Ratio
--0.47-0.14-0.93-4.09-8.24
Debt / Equity Ratio
-0.01-0.13-0.404.540.330.00
Debt / FCF Ratio
-0.17-0.23-0.06-0.27-0.35-0.01
Asset Turnover
1.571.600.410.070.01-
Inventory Turnover
1.884.415.95---
Quick Ratio
0.280.290.640.717.539.09
Current Ratio
0.550.460.850.827.729.31
Return on Equity (ROE)
----266.95%-109.08%-56.45%
Return on Assets (ROA)
-61.55%-101.46%-96.67%-78.97%-50.01%-32.77%
Return on Invested Capital (ROIC)
---281.89%-101.37%-54.86%-35.67%
Earnings Yield
-152.10%-295.34%-275.63%-119.94%-20.66%-12.55%
FCF Yield
-16.36%-195.54%-391.34%-110.49%-18.99%-10.65%
Buyback Yield / Dilution
-308.85%-398.99%-790.51%-14.63%-71.31%-44.05%
Total Shareholder Return
-308.85%-398.99%-790.51%-14.63%-71.31%-44.05%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q